Scroll Top

Beyond 50 Radio with Daniel Davis – Discussing MoneyBall Medicine

For Beyond 50’s “Emerging Technology” talks, listen to an interview with Harry Glorikian. He’ll explain what a new data-driven healthcare system could look like when implemented on a global basis. Data and cutting-edge analytics are already advancing healthcare and creating new and evolving business opportunities. When a new viral outbreak such as coronavirus occurs, having the right data and knowing how to use it can be the keys to containing the crisis — and saving lives. With accurate data, we can identify new threats, warn at-risk populations, mobilize a rapid response, and develop effective diagnostic tests and vaccines.

About Harry Glorikian

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.

He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Harry holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.